KIORA PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
KIORA PHARMACEUTICALS, INC. (KPRX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $50.74 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $50.74K, a 55.73% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $1.23K.
- KIORA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $1.60K.
- KIORA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $336.51K.
- KIORA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $114.75K, a 107.07% increase from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $55.41K, a 82.31% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $50.74K 10-Q · filed 2026-08-07 | $51.97K derived: sum of 3 quarters · filed 2026-08-07 | $53.57K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $50.74K 10-Q · filed 2026-05-08 | $51.97K derived: sum of 2 quarters · filed 2026-05-08 | $53.57K derived: sum of 3 quarters · filed 2026-05-08 | $272.63K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $1.23K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.83K derived: sum of 2 quarters · filed 2026-03-25 | $221.89K derived: sum of 3 quarters · filed 2026-08-07 | $336.51K 10-K · filed 2026-03-25 |
| 2025-09-30 | $1.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $220.66K derived: sum of 2 quarters · filed 2026-08-07 | $335.28K 10-Q · filed 2025-11-07 | $335.28K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $219.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $333.68K 10-Q · filed 2026-08-07 | $333.68K derived: sum of 3 quarters · filed 2026-08-07 | $333.68K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $114.62K 10-Q · filed 2026-05-08 | $114.62K derived: sum of 2 quarters · filed 2026-05-08 | $114.62K derived: sum of 3 quarters · filed 2026-05-08 | $114.62K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 derived: sum of 3 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | $114.75K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | $114.75K derived: sum of 3 quarters · filed 2025-08-08 | $114.75K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | $114.75K derived: sum of 2 quarters · filed 2025-05-09 | $114.75K derived: sum of 3 quarters · filed 2025-05-09 | |
| 2023-12-31 | $114.75K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $114.75K derived: sum of 2 quarters · filed 2025-03-25 | $114.75K 10-K · filed 2025-03-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $55.41K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $55.41K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $55.41K 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $313.31K 10-K · filed 2023-03-23 | |||
| 2020-12-31 | $166.82K 10-K/A · filed 2022-07-07 | |||
| 2019-12-31 | -$136.68K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04 | -$79.64K derived: sum of 2 quarters · filed 2020-03-04 | -$27.16K derived: sum of 3 quarters · filed 2020-03-04 | $109.51K 10-K · filed 2020-03-04 |
| 2019-09-30 | $57.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $109.51K derived: sum of 2 quarters · filed 2019-11-07 | $246.19K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $52.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $189.15K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $136.68K 10-Q · filed 2019-05-08 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |